New monoclonal antibody could be a game-changer in treating rare liver disease by reducing inflammation and fibrosis, says new study
A new monoclonal antibody called nebokitug offers fresh hope to patients who have primary sclerosing cholangitis (PSC), because this rare liver disease has limited treatment options until now, except for a transplant. The first set of trials, led by University of California-Davis, US, (Published in the American Journal of Gastroenterology) shows that the treatment maintains…